an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody (BsAb) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). The FDA’s decision ...

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible ...

Tecvayli (teclistamab) is an off-the-shelf bispecific antibody targeting both BCMA and CD3 which is also under review at the FDA and if approved will slot into J&J's myeloma therapy portfolio ...

With a second approach, BCMA-expressing cells can be targeted with ‘bi-specific’ antibodies made up of two parts: one that binds to CD3 receptors on T cells, and another that binds to BCMA.

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

CDR111, CDR-Life’s newest clinical candidate, is a trispecific molecule targeting CD19, BCMA and CD3, designed to achieve immune reset through broad B cell depletion. This novel therapeutic ...